pomalidomide has been researched along with Innate Inflammatory Response in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Greig, NH; Lecca, D; Rais, R; Scerba, MT; Siegler, MA; Tweedie, D | 1 |
| Schmidt, C | 1 |
| Dubey, P; Gemechu, Y; Kishimoto, T; Millrine, D; Miyata, H; Nakahama, T; Nyati, K; Ripley, B; Tei, M | 1 |
| Abdel-Wahab, O; Barbui, T; Barosi, G; Bernard, OA; Bhalla, K; Cazzola, M; Crispino, JD; Finazzi, G; Gisslinger, H; Gotlib, J; Guglielmelli, P; Gupta, V; Hoffman, R; Kiladjian, JJ; Kralovics, R; Mughal, T; Noel, P; Odenike, O; Pardanani, A; Tefferi, A; Thiele, J; Van Etten, RA; Vannucchi, AM | 1 |
| Clarke, IA; Dalgleish, AG; Dredge, K; Marriott, JB; Muller, G; Stirling, D | 1 |
1 trial(s) available for pomalidomide and Innate Inflammatory Response
| Article | Year |
|---|---|
Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.
Topics: Adjuvants, Immunologic; Adult; Aged; Antibodies, Monoclonal; Antigens, CD; CD3 Complex; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Female; Humans; Inflammation; Lenalidomide; Lipopolysaccharides; Lymphocyte Activation; Male; Middle Aged; Neoplasms; Phosphodiesterase Inhibitors; Receptors, Interleukin-2; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type II; Signal Transduction; Solubility; Thalidomide; Tumor Necrosis Factor-alpha | 2002 |
4 other study(ies) available for pomalidomide and Innate Inflammatory Response
| Article | Year |
|---|---|
Thionated aminofluorophthalimides reduce classical markers of cellular inflammation in LPS-challenged RAW 264.7 cells.
Topics: Animals; Biomarkers; Humans; Inflammation; Lipopolysaccharides; Mice; Nitrites; RAW 264.7 Cells; Thalidomide; Tumor Necrosis Factor-alpha | 2022 |
The struggle to do no harm in clinical trials.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD19; Child; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Immunotherapy; Inflammation; Lenalidomide; Male; Neoplasms; Nivolumab; Prognosis; Programmed Cell Death 1 Receptor; Risk Management; T-Lymphocytes; Thalidomide; Treatment Outcome; Vidarabine | 2017 |
Immunomodulatory drugs inhibit TLR4-induced type-1 interferon production independently of Cereblon via suppression of the TRIF/IRF3 pathway.
Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Animals; Cells, Cultured; Clustered Regularly Interspaced Short Palindromic Repeats; Immunologic Factors; Immunosuppression Therapy; Inflammation; Interferon Regulatory Factor-3; Interferon Type I; Lenalidomide; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Nerve Tissue Proteins; Signal Transduction; Thalidomide; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2016 |
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium.
Topics: Clinical Trials as Topic; Disease Progression; DNA Methylation; DNA, Neoplasm; Drugs, Investigational; Genes, Neoplasm; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Histone Deacetylase Inhibitors; Humans; Inflammation; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Myeloproliferative Disorders; Neoplasm Proteins; Polyethylene Glycols; Prognosis; Recombinant Proteins; Thalidomide; Treatment Outcome | 2012 |